In a nutshell This study investigated the effectiveness and safety of preventative antibiotic treatment with clarithromycin (Biaxin) to prevent skin-related side effects associated with panitumumab (Vectibix) treatment for patients with metastatic colorectal cancer (mCRC). The data showed that clarithromycin administered daily along with a simple...Read More
Ongoing treatment(s)-Biological therapy Posts on Medivizor
Evaluating the final effectiveness and safety outcomes of neratinib in patients with early stage HER2+/HR+ breast cancer.
In a nutshell This study reported the final effectiveness and safety outcomes of neratinib treatment in patients with early-stage HER2+/HR+ breast cancer. The data showed that neratinib significantly improved invasive disease-free survival in these patients who initiated treatment within 1 year of trastuzumab-based therapy. Some background...Read More
How does durvalumab impact the treatment of unresectable stage III non-small cell lung cancer based on previous treatment?
In a nutshell This study looked at the outcomes of durvalumab (Imfinzi) in patients with unresectable (cannot be surgically removed) stage 3 non-small cell lung cancer (NSCLC) who received different combinations of chemoradiotherapy (CRT) previously. The authors found that the use of durvalumab improved survival in all patients previously treated...Read More
In a nutshell This study looked at 5-year outcomes of patients with previously treated advanced non-small-cell lung cancer (NSCLC) taking nivolumab (Opdivo) compared to docetaxel (Taxotere). The authors found that nivolumab continued to improve the outcomes of these patients after 5 years. Some background NSCLC is the most common...Read More
Is heart monitoring needed in patients with HER2-positive metastatic breast cancer using trastuzumab?
In a nutshell This article looked at the occurrence of heart-related side effects in patients with HER2-positive metastatic breast cancer (mBC) receiving trastuzumab (Herceptin). The authors found that non-smoking patients with a good heart function before receiving treatment have a low risk of heart toxicity (HT) after 4 years...Read More
Can tumor mutation burden be used as a predictive biomarker to immune checkpoint inhibitors for non-small cell lung cancer?
In a nutshell This article looked at the use of tumor mutation burden (TMB) to predict response to immune checkpoint inhibitor (ICI) therapy in patients with non-small cell lung cancer (NSCLC). The authors found that TMB is a promising biomarker that can predict the effectiveness of ICI therapy in advanced NSCLC. Some background NSCLC...Read More
Evaluating the effectiveness and safety of bevacizumab biosimilar in patients with metastatic colorectal cancer
In a nutshell This study compared the effectiveness and safety of bevacizumab biosimilar (BE1040V) to the reference drug (Avastin) in the treatment of patients with metastatic colorectal cancer (mCRC). Researchers suggested that the effectiveness and safety of the biosimilar were similar to the reference drug bevacizumab. Some...Read More
In a nutshell This article reviewed the skin side effects caused by anti-PD-1 biological therapy. Some background Anti-PD-1 is a type of biological therapy that has significantly improved treatment results for patients with certain types of cancer. It works by blocking PD-1, a molecule that cancer cells use to switch off the immune...Read More
Can antibiotics and proton pump inhibitors alter the effectiveness of treatment for patients with non-small cell lung cancer?
In a nutshell This study examined the effects of antibiotics or proton pump inhibitor (PPI) drugs on treatment for patients with non-small cell lung cancer (NSCLC). The authors found that both antibiotics and PPIs reduced the effectiveness of biological therapy but not chemotherapy. Some background Not all patients with NSCLC respond to...Read More
In a nutshell The study evaluated the occurrence and risks of joint/muscle pain as side effects of ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL). The authors found that 36% of patients developed joint/muscle pain and most were younger and females receiving ibrutinib as the first treatment. Some background Ibrutinib kills...Read More
In a nutshell This study examined if certain immunotherapy drugs increased the risk of developing side effects in the gut in patients with cancer also receiving chemotherapy. The results showed that immunotherapy drugs increased the risks of developing gut-related side effects compared to chemotherapy alone. Some background Immunotherapy drugs that...Read More
In a nutshell This study wanted to see how well the medication afatinib (Giotrif) works in real-life settings, outside of clinical trials in patients with advanced non-small cell lung cancer (NSCLC). The study found that patients treated with afatinib had a good response rate and survival. Some background There are many...Read More